Entero Therapeutics (NASDAQ:GRDX) Issues Quarterly Earnings Results

Entero Therapeutics (NASDAQ:GRDX) posted its quarterly earnings results on Wednesday. The company reported ($0.82) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.04 million for the quarter.

Entero Therapeutics Price Performance

NASDAQ:GRDX opened at $4.61 on Wednesday. Entero Therapeutics has a 1-year low of $1.06 and a 1-year high of $5.84. The firm has a market cap of $15.49 million, a price-to-earnings ratio of -2.73 and a beta of 1.38. The company has a fifty day moving average of $2.71.

Hedge Funds Weigh In On Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. DRW Securities LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:GRDX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned 1.45% of Entero Therapeutics as of its most recent SEC filing. 12.30% of the stock is currently owned by hedge funds and other institutional investors.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.